Brooklyn ImmunoTherapeutics, Inc.(NYSE Amex Equities : BTX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.36%||164.62||0.7%||$987.18m|
|MRK||Merck & Co., Inc.||-0.50%||71.61||0.7%||$796.28m|
|LLY||Eli Lilly & Co.||-0.47%||229.96||1.1%||$594.20m|
|BMY||Bristol-Myers Squibb Co.||0.03%||61.25||1.0%||$551.71m|
|RPRX||Royalty Pharma Plc||0.31%||38.50||0.1%||$119.08m|
|NVO||Novo Nordisk A/S||-0.94%||101.42||0.1%||$109.34m|
|APLS||Apellis Pharmaceuticals, Inc.||0.62%||34.21||0.0%||$96.93m|
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.